IPP Bureau
Briefs: Panacea Biotec, Lotus Eye Hospital and Uflex
By IPP Bureau - October 04, 2025
Panacea Biotec receives Rs. 315 crore LoA from UNICEF
FDA issues CRL for Sentynl’s copper histidinate for treatment of Menkes disease
By IPP Bureau - October 04, 2025
Supriya Lifescience’s Ambernath facility receives WHO GMP certification
By IPP Bureau - October 04, 2025
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
IPA welcomes Dr. Sharvil Patel as President and Glenn Saldanha as Vice President
By IPP Bureau - October 04, 2025
Genmab to acquire Merus for $8 billion
By IPP Bureau - October 03, 2025
Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio
A. P. Rameswara Rao appointed National President of BDMAI
By IPP Bureau - October 03, 2025
A Post Graduate in Science faculty and has a wide experience spanning over 35 years in the field of manufacturing Bulk Drugs and Active Pharmaceutical Intermediaries
Novartis to launch DTP platform for Cosentyx in US
By IPP Bureau - October 01, 2025
Through the new DTP platform, Novartis will make Cosentyx available to patients at a price that reflects the average savings typically retained by insurers and pharmacy benefit managers
ACL Digital acquires US-based CRO Symbiance to expand clinical research capabilities
By IPP Bureau - October 01, 2025
The acquisition positions ACL Digital as an end-to-end provider of global clinical research and data CRO solutions
Lupin receives FDA approval Rivaroxaban for oral suspension
By IPP Bureau - October 01, 2025
The product will be manufactured at Lupin’s Chhatrapati Sambhajinagar facility in India
Pfizer agrees to slash prescription drug prices for Americans
By IPP Bureau - October 01, 2025
Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%
AbbVie begins construction of $70 million biologics manufacturing site in US
By IPP Bureau - October 01, 2025
The expansion will significantly enhance AbbVie’s ability to meet growing global demand for biologics, particularly in oncology and immunology
DPIIT and Thermo Fisher Scientific launch BioVerse challenge to fast-track India’s biotech future
By IPP Bureau - October 01, 2025
India currently hosts more than 10,075 biotech startups
AbbVie seeks FDA approval for Pivekimab Sunirine to treat rare, aggressive blood cancer
By IPP Bureau - October 01, 2025
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
Winrevair cuts risk of PAH progression by 76% in phase 3 Hyperion trial
By IPP Bureau - October 01, 2025
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
